IENRX Mutual Fund

NAV$13.38

Fund Essentials - as of Mar 31, 2026

Net Assets
$2M
Expense Ratio
0.82%
Dividend Yield (Current)
1.10%
Holdings
35
Inception Date
Jul 31, 2014
Fund Family
Nomura Asset Management Co Ltd
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Annually

Performance

YTD+13.48%
1 Year+35.64%
3 Year+10.42%
5 Year+14.27%
10 Year+1.43%

Asset Allocation

Stocks: 99.71%
Cash: 0.22%
Other: 0.07%

Price Chart (6M)

Loading chart data...

Top Holdings

View All →
TickerNameWeight
DARDarling International Inc4.08%
NESTE:FINeste Oyj4.03%
AEEAmeren Corp.3.78%
VLOValero Energy Corp.3.78%
EDPR:MAEdp Renovaveis Sa3.64%
Top 10 Concentration: 37.18%Report Date: Mar 31, 2026
Download all 35 holdings for IENRX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Dividend Yield (Current)
1.10%
Frequency
Annually
Latest Distribution
$0.13
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO
See how IENRX ranks against its peers
Category rank, peer-average returns and outperformance, updated daily.
$49$29/mo
Claim the $29 launch price
First 500 subscribers, then $49/mo. Cancel anytime. From MarketXLS, trusted since 2014.

IENRX Mutual Fund Overview

IENRX Mutual Fund (Nomura Climate Solutions Fund Class R6) is managed by Nomura Asset Management Co Ltd with $1.7M in net assets. IENRX expense ratio is 0.82%, holding 35 positions across sectors including Unknown, Materials, Utilities. Inception date: 2014-07-31.

IENRX performance shows a YTD return of 13.48%. The 1-year return is 35.64% and the 5-year return is 14.27%. IENRX dividend yield stands at 1.10%, paid annually.

IENRX top holdings include Darling International Inc (4.1%), Neste Oyj (4.0%), Ameren Corp. (3.8%), Valero Energy Corp. (3.8%), Edp Renovaveis Sa (3.6%). View all IENRX holdings, sector breakdown, or dividend history.

IENRX can be compared against other funds using the overlap calculator or side-by-side comparison tool. IENRX alternatives are available via the screener, along with tax-loss harvesting opportunities.